Current Assets
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value
Moderna AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value increased by 800.0% to $9.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 350.0%, from $2.00M to $9.00M. Over 4 years (FY 2021 to FY 2025), AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value shows a downward trend with a -62.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2019
Last reportedQ1 2026May 1, 2026
Metric ID:
afs_trading_securities_unrealized_loss_lt_12m_fvHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.00M | $271.00M | $357.00M | $373.00M | $241.00M | $59.00M | $46.00M | $14.00M | $4.00M | $11.00M | $9.00M | $1.00M | $6.00M | $2.00M | $2.00M | $0.00 | $1.00M | $9.00M |
| QoQ Change | — | +421.2% | +31.7% | +4.5% | -35.4% | -75.5% | -22.0% | -69.6% | -71.4% | +175.0% | -18.2% | -88.9% | +500.0% | -66.7% | +0.0% | -100.0% | — | +800.0% |
| YoY Change | — | — | — | — | +363.5% | -78.2% | -87.1% | -96.2% | -98.3% | -81.4% | -80.4% | -92.9% | +50.0% | -81.8% | -77.8% | -100.0% | -83.3% | +350.0% |
Range$0.00 – $373.00M
CAGR-33.8%
Avg YoY Growth-13.9%
Median YoY Growth-81.6%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at Other Companies
Frequently Asked Questions
- What is Moderna's afs and trading securities - unrealized loss position (<12 months) fair value?
- Moderna (MRNA) reported afs and trading securities - unrealized loss position (<12 months) fair value of $9.00M in Q1 2026.
- How has Moderna's afs and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?
- Moderna's afs and trading securities - unrealized loss position (<12 months) fair value increased by 350.0% year-over-year, from $2.00M to $9.00M.
- What is the long-term trend for Moderna's afs and trading securities - unrealized loss position (<12 months) fair value?
- Over 4 years (2021 to 2025), Moderna's afs and trading securities - unrealized loss position (<12 months) fair value has grown at a -62.8% compound annual growth rate (CAGR), from $52.00M to $1.00M.